본문

ScienceON 검색

ScienceON '특허' 검색

MORE
국가과학기술정보센터(ScienceON) 특허검색
No 제목 / 내용
1 POCKETED SPRING ASSEMBLY INCLUDING CUSHION PADS AND BUCKLING MEMBERS / P PROPERTY MANAGEMENT COMPANY
A pocketed spring assembly (12, 12a, 12b, 12', 12d, 12e) comprises a plurality of parallel strings of springs (26, 26a, 26b, 26c, 27, 126, 26d, 26d, 26cc), each string joined to at least one adjacent string, each string (26, 26a, 26b, 26c, 27, 126, 26d, 26e, 26cc) comprising one piece of fabric folded into first and second opposed plies. Outer pockets (34, 34b, 92, 100, 110, 292, 200, 210) are formed along each string by transverse seams (52, 152, 252) joining the first and second plies (47, 49). One pocketed spring (82, 82b), at least one cushion pad (54, 54a) and at least one buckling member (55, 55a, 55b, 55c, 55d, 55e, 55f, 55g, 55h) are positioned in each outer pocket. At least one cushion pad (54, 54a), at least one buckling member (55, 55a, 55b, 55c, 55d, 55e, 55f, 55g, 55h) or any combination thereof may be individually pocketed inside an outer pocket (34, 34b, 92, 100, 110, 292, 200, 210).
2 Synthesis of N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide / Xu, Yong
A method for preparing BTK inhibitor CC-292 of formula 1, comprising: (1) contacting a compound of formula 2 with a compound of formula 3 to obtain a compound of formula 4; (2) contacting the compound of formula 4 with a compound of formula 5 to obtain a compound of formula 6; (3) contacting the compound of formula 6 with trifluoromethanesulfonic anhydride to obtain a compound of formula 7; and (4) contacting the compound of formula 7 with a compound of formula 8 to obtain the compound of formula 1,

ScienceON '논문' 검색

MORE
ScienceON 논문 검색
No 제목 / 내용
1 A Phase 1b, Multi-Center, Open-Label Study of Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-Cell Lymphoma: CC-122-DLBCL-001
American Society of Hematology , 2016 ; Vol. 128 , Issue 22
2 B cell receptor pathway in chronic lymphocytic leukemia: specific role of CC-292
Dove Medical Press , 2014 ; Vol. 3 , Issue 22
3 Inhibition of Btk with CC-292 Provides Early Pharmacodynamic Assessment of Activity in Mice and Humans
American Society for PharmacologyExperimental Therapeutics , 2013 ; Vol. 346 , Issue 2
4 Target Engagement, Pathway Inhibition, and Efficacy Of The Bruton’s Tyrosine Kinase (Btk) Inhibitor CC-292
American Society of Hematology , 2013 ; Vol. 122 , Issue 21
5 Prevention of Bone Destruction by Mechanical Loading Is Not Enhanced by the Bruton’s Tyrosine Kinase Inhibitor CC-292 in Myeloma Bone Disease
MDPI , 2021 ; Vol. 22 , Issue 8
6 Spebrutinib (CC-292) Affects Markers of B Cell Activation, Chemotaxis, and Osteoclasts in Patients with Rheumatoid Arthritis: Results from a Mechanistic Study
Springer Healthcare , 2020 ; Vol. 7 , Issue 1
7 Inhibition of Btk with CC-292 Provides Early Pharmacodynamics Assessment of Activity in Mice and Humans
American Society for PharmacologyExperimental Therapeutics , 2013 ; Vol. 346 , Issue 2
8 Phase I study of single-agent CC-292, a highly selective Bruton’s tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia
Haematologica , 2016 ; Vol. 101 , Issue 7
9 A Novel Bruton′s Tyrosine Kinase Inhibitor CC-292 In Combination With The Proteasome Inhibitor Carfilzomib Iimpacts Multiple Myeloma Bone Microenviroment With Resultant Anti-Myeloma Activity
American Society of Hematology , 2013 ; Vol. 122 , Issue 21
10 Phase 1 Study Of Single Agent CC-292, a Highly Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
American Society of Hematology , 2013 ; Vol. 122 , Issue 21

ScienceON '보고서' 검색

MORE

QuickMenu